

Lisata Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's lead investigational product candidate, LSTA1 (formerly known as CEND-1), is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform. For more information on the Company, please visit [www.lisata.com](http://www.lisata.com).

## INVESTMENT HIGHLIGHTS

## MARKET SNAPSHOT

<ul style="list-style-type: none"> <li>Nasdaq-listed with a focused mid-late-stage clinical development pipeline and a promising preclinical platform</li> <li>Stable finances: ~\$76 million cash &amp; investments as of 9/15/22; no debt</li> <li>Proprietary field-leading technology in underserved global indications backed by a strong IP portfolio</li> <li>Platform technology "validated" by strong existing partnerships with potential for many others</li> <li>Multiple potential value creating data and business development events projected in the next 12-24 months</li> <li>Seasoned management with domain expertise along with big pharma and emerging pharma experience</li> </ul>	<p><b>TICKER SYMBOL</b> LSTA</p> <p><b>EXCHANGE</b> NASDAQ</p> <p><b>52-WEEK PRICE RANGE</b> \$4.38 - \$18.60</p> <p><b>CASH &amp; INVESTMENTS (9/15/2022)</b> ~\$76 million</p> <p><b>FISCAL YEAR-END</b> December 31</p>
---	--

## ROBUST PORTFOLIO OF DEVELOPMENT CANDIDATES

Sponsor/Funding Partner	Trial Products	Indication	Development Stage	Next Development Milestone
<b>CendR Platform™ Programs</b>				
Lisata (Global)	Gemcitabine/nab-paclitaxel ± LSTA1	First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	Phase 2/3 adaptive	FDA feedback 4Q22 Trial initiation planned 1Q/2Q23
AGITG (Australia/New Zealand)	Gemcitabine/nab-paclitaxel ± LSTA1		Phase 2b (ASCEND)	Enrollment completion target 4Q23 Data expected 2024
Qilu (China)	Gemcitabine/nab-paclitaxel ± LSTA1		Phase 1b/2	Preliminary data expected 2H23
Roche/Lisata (Multi-national)	LSTA1 + nab-paclitaxel + gemcitabine ± atezolizumab		Phase 1b/2	Trial initiation target 1Q23
KUCC-IIT (U.S.)	LSTA1 + FOLFIRINOX + panitumumab*	Pancreatic, Colon and Appendiceal Cancers	Phase 1b/2 (CENDIFOX)	Enrollment completion target 4Q23 Data expected 2024
Lisata (U.S.)	LSTA1 in combination with SoC	Various Solid Tumors	Phase 2a	Trial initiation planned 1Q/2Q23
Lisata (U.S.)	TPN development candidate		Preclinical	Development candidate ID target 2023 Phase 1 planned for 2024
<b>CD34+ Platform Programs</b>				
Lisata (U.S.)	XOWNA® (LSTA16)	Coronary Microvascular Dysfunction	Phase 2b (FREEDOM)	Partner sought to advance development
Lisata (Japan)	HONEDRA® (LSTA12)	Critical Limb Ischemia and Buerger's Disease	Phase 2	PMDA consultation underway
Lisata (U.S.)	LSTA201	Diabetic Kidney Disease	Phase 1b – PoC	Data expected 1Q23

\*Panitumumab may be added for colorectal or appendiceal patients without Ras mutation